Global Diabetic Neuropathy Treatment Market Report and Forecast 2023-2031

Global Diabetic Neuropathy Market Report and Forecast 2023-2031

Global Diabetic Neuropathy Market Outlook

The global diabetic neuropathy market size was valued at USD 4.7 billion in 2022 and is projected to grow at a CAGR of 8.2% during the forecast period of 2023-2031 to reach a value of USD 9.55 billion by 2031. The market growth can be attributed to the increasing prevalence of diabetes worldwide and the rising awareness about the complications associated with diabetes, including diabetic neuropathy.

Global Diabetic Neuropathy Market: Introduction

Diabetic neuropathy refers to nerve damage caused by diabetes. High blood sugar levels can damage nerves throughout the body, leading to various symptoms, such as numbness, pain, and weakness. Diabetic neuropathy is a common complication of diabetes, affecting up to 50% of people with the disease.

The increasing prevalence of diabetes, coupled with the ageing population and rising awareness about diabetic complications, is driving the demand for diabetic neuropathy treatment. Additionally, advancements in treatment options and the development of new therapies are expected to propel market growth. Rapidly rising geriatric population contributes to the growth of the diabetic neuropathy market, as older individuals are more likely to develop diabetes and related complications. The increasing number of older adults worldwide will lead to a higher demand for diabetic neuropathy treatments. Government initiatives to raise awareness about diabetes and its complications, along with the provision of funding for research and development, are expected to bolster the diabetic neuropathy market growth.

Diabetic Neuropathy Epidemiology

According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. Diabetic neuropathy affects a significant proportion of people with diabetes, with varying degrees of severity. The risk of developing diabetic neuropathy increases with age and the duration of diabetes. Proper diabetes management, including blood sugar control and maintaining a healthy lifestyle, can help prevent or delay the onset of diabetic neuropathy.

Diabetic Neuropathy Market Segmentations

The market can be segmented based on type, treatment methods, and major region:

Market Breakup by Type

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
Market Breakup by Treatment
  • Antidepressants
  • Anti-seizure Medications
  • Anticonvulsants
  • Electrical Nerve Stimulation
  • Topical Medications
  • Others
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Diabetic Neuropathy Market Analysis

North America currently dominates the global diabetic neuropathy market, owing to factors such as a high prevalence of diabetes, advanced healthcare infrastructure, and increasing awareness about diabetic complications. Europe is also a significant market for diabetic neuropathy treatment, driven by a large population base, government initiatives to address diabetes-related issues, and the presence of key market players in the region.

Asia Pacific is also expected to be the fastest-growing region in the diabetic neuropathy market, due to the large population base, rapidly increasing prevalence of diabetes, and growing awareness of diabetic complications.

The increasing adoption of novel treatment options, such as monoclonal antibodies and stem cell therapy, along with advancements in diagnostic tools, are expected to further drive the growth of the diabetic neuropathy market in the coming years. However, challenges such as the high cost of treatment and limited access to healthcare services in low- and middle-income countries may hinder market growth to some extent. Efforts are being made to address these barriers and improve access to diabetic neuropathy treatment globally.

Key Players in the Global Diabetic Neuropathy Market

The report provides a detailed analysis of the key players involved in the diabetic neuropathy market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • NeuroMetrix, Inc
  • Allergan PLC
  • Pfizer, Inc
  • Eli Lilly and Company
  • Novartis AG
  • Others

*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Diabetic Neuropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Diabetic Neuropathy Treatment Market
8.1 Global Diabetic Neuropathy Treatment Market Overview
8.2 Global Diabetic Neuropathy Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Diabetic Neuropathy Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Diabetic Neuropathy Treatment Market Forecast Value (2023-2031)
8.3 Global Diabetic Neuropathy Treatment Market by Disease Type
8.3.1 Market Overview
8.3.1.1 Peripheral Neuropathy
8.3.1.2 Autonomic Neuropathy
8.3.1.3 Proximal Neuropathy
8.3.1.4 Focal Neuropathy
8.4 Global Diabetic Neuropathy Treatment Market by Treatment Method
8.4.1 Market Overview
8.4.1.1 Drugs
8.4.1.1.1 Analgesics
8.4.1.1.2 Antidepressant
8.4.1.1.3 Anticonvulsants
8.4.1.1.4 Others
8.4.1.2 Transcutaneous Electrical Nerve Stimulation (TENS)
8.4.1.3 Non-Steroidal Anti-Inflammatory Drugs
8.4.1.4 Others
8.5 Global Diabetic Neuropathy Treatment Market by End User
8.5.1 Market Overview
8.5.1.1 Hospitals And Clinics
8.5.1.2 Retail Pharmacy
8.5.1.3 Online Pharmacy
8.6 Global Diabetic Neuropathy Treatment Market by Treatment Channel
8.6.1 Public
8.6.2 Private
8.7 Global Diabetic Neuropathy Treatment Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 North America Diabetic Neuropathy Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Diabetic Neuropathy Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Diabetic Neuropathy Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Diabetic Neuropathy Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Diabetic Neuropathy Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Diabetic Neuropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicator
14.5 Key Price Indicator
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Novartis AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Pfizer Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Glenmark Pharmaceuticals Ltd.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Eli Lilly and Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Abbott Laboratories
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 F. Hoffmann-La Roche Ltd
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Johnson & Johnson Services, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 GlaxoSmithKline Plc
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Lupin Ltd
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Depomed, Inc
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Astellas Pharma Inc
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Meda Pharma GmBH & Co. KG
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Global Diabetic Neuropathy Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings